Development of an ERAD-hijacking technology overcomes the challenges of current targeted protein degradation approaches to achieve degradation of transmembrane proteins.

Nature Biotechnology, Published online: 18 March 2026; doi:10.1038/s41587-026-03054-y

Solid tumors are sensitized to anti‑PD‑L1 immunotherapy by engineered E. coli to produce nitric oxide.